Sagent Pharmaceuticals has re-introduced an antiarrhythmic agent Amiodarone HCl Injection as an improved prefilled plastic syringe compatible with standard I.V. pumps.
Featuring Sagent's PreventIV Measures packaging and labeling to help reduce medication errors, Amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy.
Further, the product is indicated for patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication.
Patients may be transferred to oral amiodarone therapy, during or after treatment with amiodarone.
Sagent Pharmaceuticals is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific prominence on injectables.
